@article{43175ac85c294c7589d66e5e12bf4078,
title = "Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?",
author = "Stefan Leucht and Levine, \{S. Z.\} and M. Samara and A. Cipriani and Davis, \{J. M.\} and Furukawa, \{T. A.\}",
note = "Funding Information: In the last three years Stefan Leucht received honoraria for consulting from LB Pharma, Lundbeck, Otsuka, TEVA, LTS Lohmann, Geodon Richter, Recordati, Boehringer Ingelheim, and Sandoz. For lectures from Janssen, Lilly, Lundbeck, Otsuka, SanofiAventis, Servier and Sunovion. Over 3 years ago, Dr Levine received honoraria and/or research support, and/or consultancy fees and/or travel support from: Shire Pharmaceuticals, F. Hoffmann-La Roche and Eli Lilly. Toshi A Furukawa has received lecture fees from Meiji, Mitsubishi-Tanabe, MSD and Pfizer. He has received research support from Mitsubishi-Tanabe. John M Davis and Myrto Samara have no conflict of interest to declare.",
year = "2018",
month = oct,
day = "1",
doi = "10.1007/s00406-018-0940-0",
language = "English",
volume = "268",
pages = "621--623",
number = "7",
}
SDG 3 Good Health and Well-being